Camille Bedrosian Sells 12,039 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille Bedrosian sold 12,039 shares of the business’s stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $14.58, for a total value of $175,528.62. Following the completion of the transaction, the insider directly owned 182,336 shares in the company, valued at $2,658,458.88. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $13.42 on Friday. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -5.37 and a beta of -0.33. The business’s 50-day moving average is $10.29 and its 200-day moving average is $7.00. Amylyx Pharmaceuticals, Inc. has a 1 year low of $2.60 and a 1 year high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.02). Analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its holdings in Amylyx Pharmaceuticals by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after purchasing an additional 143,065 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Amylyx Pharmaceuticals in the 1st quarter worth approximately $5,697,000. Invesco Ltd. purchased a new position in shares of Amylyx Pharmaceuticals in the 1st quarter worth approximately $162,000. American Century Companies Inc. boosted its stake in shares of Amylyx Pharmaceuticals by 80.4% in the 1st quarter. American Century Companies Inc. now owns 107,014 shares of the company’s stock worth $379,000 after buying an additional 47,704 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Amylyx Pharmaceuticals in the 1st quarter worth approximately $20,170,000. 95.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AMLX shares. Guggenheim boosted their target price on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Bank of America boosted their target price on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amylyx Pharmaceuticals in a research report on Saturday, September 27th. UBS Group raised Amylyx Pharmaceuticals to a “hold” rating in a research report on Tuesday, June 24th. Finally, Citigroup started coverage on Amylyx Pharmaceuticals in a research report on Tuesday, June 17th. They issued a “buy” rating and a $12.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $14.75.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.